Control of growth in neuroendocrine gastro-enteropancreatic tumours

Digestion

Volumn 57, Issue , 1996, Pages 69-71

  Arnold, R ^a   Frank, M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Chemotherapy; Gastro enteropancreatic tumours; Interferons; Octreotide

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; SOMATOSTATIN DERIVATIVE;

ARTIFICIAL EMBOLISM; CANCER INHIBITION; CONFERENCE PAPER; GASTROINTESTINAL TUMOR; GROWTH RATE; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 0029954058     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201400     Document Type: Article

References (19)

1. Capella C, Heitz PU, Hofler H, Solcia E, Klbppel G: Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Digestion 1994;55(suppl 3): 11-23.
2. Evers BM, Parekh D, Townsend CM, et al.: Somatostatin and analogues in the treatment of cancer: A review. Ann Surg 1991:213:190-198.
3. Liebow C, Reilly C, Serrano M, et al.: Somatostatin analogues inhibit growth of pancreatic cancer by stimulation of tyrosine phosphatase. Proc Natl Acad Sci USA 1989:86:2003-2006.
4. von Werder K, Losa M, Muller OA, et al.: Treatment of mctastasing GRF producing tumour with a long-acting somatostatin analogue. Lancet 1984;ii:282-283.
5. Kraenzlin ME, Ch’ng JC, Wood SM, et al.: Can inhibition of hormone secretion be associated with endocrine tumour shrinkage? Lancet 1983;ii: 1501-1504.
6. Kraenzlin ME, Ch’ng JC, Wood SM, et al.: Long term treatment of a VIPonia with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metas-tases. Gastroenterology 1985:88:185-187.
7. Clemts D, Elias E: Regression of metastatic VIPoma with somatostatin analogue SMS 201 -995. Lancet 1985:i:874-875.
8. Shepherd JJ, Senator GB: Regression of liver metastascs in patients with gastrin-secreting tumour treated with SMS 201-995. Lancet 1986; i:574.
9. Wiedenmann B, Rath U, Racdsch R, et al.: Tumour regression of an ileal carcinoid under the treatment with somatostatin analogue SMS 201-995. Klin Wochcnschr 1988:66:75-77.
10. Creutzfeldt W, Bartsch HH, Jacubaschke U, et al.: Treatment of gastrointestinal endocrine tumours with interfcron-alpha and octreotide. Acta Oncol 1991;30:529-535.
11. Vinik AL, Tsai ST, Moattari AR, et al.: Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumours and diarrhea syndromes. Am J. Med 1986:81: 23-40.
12. Gordon PH: NIH Conference: Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone secreting tumours of the pituitary' and gastrointestinal tract and nonneoplastic diseases of the gut. Ann Intern Med 1989:110:35-50.
13. Saltz L, Trochanowsky B, Buckley M. et al.: Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuro-endocrine tumours. Cancer 1993:72: 244-248.
14. Armul R, Trautmann ME, et al.: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroentero-pancreatic tumours. Gut. in press.
15. Eriksson B, Öberg K: Interferon therapy of malignant endocrine pancreatic tumours. Front Gastrointesl Res 1995:23:451-460.
16. Jocnsun H, Kiitkä K, Kujari H: Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenhan) 1992:126:184-185.
17. Arnold R, Frank M, Kajdan U, et al.: Kombinierte Behandlung metastasierter endokriner Tumoren des Gastrointestinaltrakts mit Oc-treotid und Interferon-Alpha. Z Gastroenterol 1994:32:193-197.
18. Moertel CG, Lcfkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozotocin-doxorubicin. strcplozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992:326:519-523.
19. Moertel CG, Kvols LK, O'Connell MJ, Rubin I: Treatment of neuroendocrine carcinomas with combined etoposide and eisplatin: Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991:68:227-232.